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Abstract
Purpose Although the correlation between vitamin D and
growth hormone (GH)-insulin-like growth factor 1 (IGF1)
axis is documented, as of date, few and conflicting studies
have prospectively analyzed vitamin D before and after GH
treatment. Our aim was to evaluate as to how the condition
of GH deficiency (GHD) or GH treatment influences
vitamin D in children.
Methods Eighty Sicilian GHD children (M/F 58/22; mean
age 10.3 years), grouped according to the season of eval-
uation in group A (June–September; 41 children) and group
B (November–February; 39 children), were evaluated at
baseline and after 12 months of GH treatment.
Results Twenty-eight children (35 %) were vitamin D
insufficient and 32 (40 %) deficient at baseline, and lower
vitamin D levels were found in group B than in A
(17.3 ± 5.3 vs. 31.1 ± 11.1 ng/ml; p \ 0.001). A positive
correlation between vitamin D and baseline GH levels
(p \ 0.001) was found. After 12 months, increased vitamin
D was found both in all children (34.4 ± 16.4 vs.
24.5 ± 11.1 ng/ml; p = 0.002) and in group A (38.5 ± 14
vs. 31.1 ± 11.1 ng/ml; p \ 0.001) and B (30 ± 17.7 vs.
17.3 ± 5.3 ng/ml; p \ 0.001). Overall, only 25 (31 %)
children remained insufficient and 15 (19 %) deficient,
with an increase in prevalence of children with normal
levels (p = 0.001).
Conclusions Our data demonstrated a very high preva-
lence of hypovitaminosis D in Sicilian GHD children, with
an improvement after 12 months of GH treatment. Vitamin
D assessment should therefore be considered routinely in
GHD children both at diagnosis and during the follow-up.
Keywords Growth hormone  Vitamin D 
GH treatment  GH deficiency
Introduction
Vitamin D is essential for skeletal growth and the corre-
lation between vitamin D and the growth hormone (GH)-
insulin-like growth factor 1 (IGF1) axis is well docu-
mented. Treatment with GH in adult GH-deficient (GHD)
patients increases bone turnover parameters [1–3], though
it remains unclear whether GH acts on bone metabolism
and vitamin D directly or indirectly via increased IGF1
synthesis. Indeed, the role of GH and IGF1 in the regula-
tion of vitamin D is not fully understood. IGF1 and vitamin
D influence their respective circulating concentrations.
IGF1 stimulates expression and activity of the 1a-
hydroxylase in the kidney, increasing the circulating levels
of 1,25-dihydroxyvitamin D (1,25(OH)2D), the hormonally
active and most potent metabolite of vitamin D, responsi-
ble for all the effects of the vitamin on calcium metabolism
[4], but with a controversial relationship. Though the
administration of both GH and IGF1 raises vitamin D in
healthy subjects [5, 6], some studies show that vitamin D
concentrations do not significantly change when GH or
IGF1 levels vary substantially, as in acromegalic or GHD
subjects after starting treatment [7, 8]. On the other hand,
vitamin D seems to promote the production of IGF1 [9].
Indeed, vitamin D increases circulating IGF1 levels both in
adults [10] and children [11]. As of date, few studies, and
with controversial results, have prospectively analyzed the
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vitamin D status in children before and after GH treatment.
The aim of this study was to evaluate as to how the con-
dition of GHD or GH treatment influences vitamin D levels
in children affected by idiopathic GHD.
Materials and methods
This prospective study was located in Southern Italy
(Sicily, latitude 37N). We studied 80 prepubertal children
(58 M, 22 F; mean age 10.3 ± 3 years; range 4.3–16)
with isolated idiopathic GHD consecutively admitted to
the Section of Endocrinology of the University of Palermo
during the years 2011 and 2012 and treated with GH for at
least 12 months. We excluded children with any medical
condition or on any medications known to affect skeletal
metabolism, and those affected by multiple pituitary hor-
mone deficiency or receiving any other kind of hormonal
replacement treatment or drug and with a follow-up of
\12 months. All children, even the older ones, were in
the first or second stage of sexual development according
to the criteria of Marshall and Tanner [12]. The diagnosis
of GHD was established by the clinical, auxological and
biochemical criteria of the GH Research Society [13].
GHD was demonstrated by failure of GH to respond to the
two stimuli, with GH peaks below 10 lg/l. During the
tests, the area under the curve of GH (AUCGH) was cal-
culated and the average value between the two tests was
reported. The patients received GH once daily at bedtime
with a pen injection system. The initial daily dose was
0.025 mg/kg. During the study, the GH dose administered
was adjusted in order to maintain serum IGF-I levels
within the normal range for sex and age. In all patients, at
baseline and after 12 months of GH treatment, according
to our fixed internal protocol, we measured body height
[standard deviation (SD)], height-velocity (HV), waist
circumference (WC), IGF1, serum calcium (Ca), phos-
phate (P), bone-specific alkaline phosphatase (AP), total
25-OH-vitamin D (25-OHD) and parathyroid hormone
(PTH). Since 1,25(OH)2D levels are only a measure of
renal-derived vitamin D, we measured serum concentra-
tion of 25-OHD, a good indicator of the amount of
available vitamin D. Vitamin D was classified as follows:
vitamin D deficiency was defined as a 25-OHD \20 ng/ml
(\50 nmol/l), vitamin D insufficiency as a 25-OHD
between 20 and 30 ng/ml (50–75 nmol/l) and vitamin D
sufficiency as a 25-OHD [30 ng/ml ([75 nmol/l) [14,
15]. The study outcome considered bone metabolic
parameters at baseline and after 12 months and their
correlations with biochemical and auxological data. In
order also to evaluate the impact of seasonal variations on
vitamin D levels, the study was performed and the chil-
dren recruited in two periods: between June and
September (group A, 41 children) and between November
and February (group B, 39 children). The institutional
Ethics Committee of the University of Palermo approved
this study. At the time of hospitalization, an informed
consent for the scientific use of the data was obtained
from parents.
Hormone and biochemical assays
All biochemical data were collected after overnight fasting.
During the study period, in our laboratory the GH levels
were assayed by immunoradiometric assay (Radim,
Pomezia, Italy) and the sensitivity of the assay was
0.05 lg/l. The intra- and inter-assay coefficients of varia-
tion (CV) were 2.5–3.9 and 3.8–5.0 %, respectively. Serum
total IGF1 was assayed in the same laboratory with the
ELISA method (OCTEIA IGF-I kit, IDS Inc., Fountain
Hills, AZ, USA). The sensitivity of the method was 1.9 lg/
l. The inter- and intra-assay CV values were 7–7.1 and
2.3–3.5 %, respectively, at IGF-I levels of 90.7–186 and
66.7–120.9 lg/l, respectively. The normal ranges (males
and females combined) of total IGF-I levels (lg/l) were:
12–108 (0–1 years); 13–100 (1–3 years); 26–280
(3–6 years); 85–230 (6–9 years); 98–404 (9–12 years);
142–525 (12–15 years); 146–415 (15–20 years).
Serum Ca, P, AP and PTH levels were measured in our
centralized laboratory with standard methods. Serum
25-OHD was measured by total chemiluminescent immu-
noassay for in vitro quantitative determination of total
25-hydroxyvitamin D (D2 ? D3) in human serum and
plasma (Diasorin, Saluggia, Italy). The intra- and inter-
assay CV was 6.9–12.7 and 2.9–5.5 %, respectively.
Statistical analysis
The Statistical Package for Social Sciences SPSS version
17 was used for data analysis. Baseline characteristics were
presented as mean ± SD for continuous variables, rates
and proportions were calculated for categorical data. Nor-
mality of distribution for quantitative variables was asses-
sed with the Kolmogorov–Smirnov test. The differences
between the two groups (group A and B) of patients were
evaluated with the Mann–Whitney test (non-parametric
test), as they were continuous variables without normal
distribution.
The differences between group A and B were corrected
for chronological age through a logistic regression mod-
el.The differences between paired continuous variables
(before and 12 months after therapy) were analyzed by the
Wilcoxon test. Correlations among continuous variables
without normal distribution were determined by using the
Spearman’s test (non-parametric equivalent for Pearson
test). For categorical variables, differences were analyzed
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by means of the v2-test and Fisher’s exact test when
appropriate. A p value \0.05 was considered statistically
significant.
Results
The baseline auxological and biochemical parameters of
children are shown in Table 1.
In the entire cohort of children, the mean vitamin D
levels at baseline were 24.4 ± 11.1 ng/ml (IR 8–73.4 ng/
ml), with Ca, P, AP and PTH concentrations in the normal
range. Twenty-eight (35 %) children at baseline were
vitamin D-insufficient and 32 (40 %) vitamin D-deficient.
Only 20 (25 %) children showed normal vitamin D levels
(Table 2).
Grouping all children according to the season in which
the analysis was done, we found significantly lower vita-
min D levels in group B than in group A (17.3 ± 5.3 vs.
31.1 ± 11.1 ng/ml; p \ 0.001). This significance was
confirmed when we corrected the p value for chronological
age. No difference was found in other auxological and
biochemical parameters between the two groups of
patients, with the exception of AUCGH, which was signif-
icantly higher in group A than group B (286.9 ± 145.4 vs.
195.5 ± 158; p \ 0.001) (Table 1).
Table 1 Baseline clinical and biochemical parameters of GHD children in totality and grouped according to the season of evaluation
All children Group A (June–September) Group B (November–February) p p*
Nos. 80 Nos. 41 (51 %) Nos. 39 (49 %)
Gender
Males 58 (72.5) 26 (63) 32 (82) 0.081 –
Females 22 (27.5) 15 (37) 7 (18)
Mean ± SD Mean ± SD Mean ± SD
Chronological age (years) 10.3 ± 3 10 ± 2.9 10.7 ± 3.2 0.315 –
Height (SD) -2.1 ± 0.7 -2.0 ± 1.3 -2.1 ± 0.5 0.782 –
Weight (kg) 29.3 ± 11.5 26.9 ± 9.2 31.9 ± 13.2 0.058 –
Waist circumference (cm) 60.9 ± 10.8 58.6 ± 8.7 63.7 ± 12.6 0.079 –
AUCGH (lg/l) 242.4 ± 157.6 286.9 ± 145.4 195.5 ± 158 0.009 0.022
IGF-I (lg/l) 135.9 ± 64.6 139.1 ± 61.3 132.4 ± 69.3 0.722 –
Serum Ca (mg/dl) 9.6 ± 0.4 9.6 ± 0.4 9.5 ± 0.3 0.448 –
Serum P (mg/dl) 4.6 ± 0.5 4.5 ± 0.5 4.6 ± 0.4 0.342 –
Serum AP (IU/l) 161.2 ± 70.6 148.6 ± 33.5 175.8 ± 97 0.270 –
Serum 25OHD (ng/ml) 24.4 ± 11.1 31.1 ± 11.1 17.3 ± 5.3 \0.001 \0.001
Serum PTH (pg/ml) 32.5 ± 13.4 31.1 ± 10.8 33.8 ± 15.7 0.400 –
Ca calcium, P phosphate, AP bone-specific alkaline phosphatase, 25OHD vitamin D, PTH parathyroid hormone
p difference between group A and group B
p* difference between group A and group B corrected for chronological age
Table 2 Vitamin D levels in GHD children in totality and grouped according to the season of evaluation (group A: between June–September;
group B: between November-February) at baseline and after 12 months of GH treatment
All at
baseline
Nos. 80
All at
12 months
Nos. 80
Group A at
baseline
Nos. 41
Group A at
12 months
Nos. 41
Group B at
baseline
Nos. 39
Group B at
12 months
Nos. 39
p p* p**
No (%) No (%) No (%) No (%) No (%) No (%)
25OHD \20 32 (40) 15 (19) 7 (17) 5 (12) 25 (64) 10 (26) 0.005 0.754 0.001
25OHD 20–30 ng/ml 28 (35) 25 (31) 14 (34) 9 (22) 14 (36) 16 (41) 0.736 0.325 0.816
25OHD [30 ng/ml 20 (25) 40 (50) 20 (49) 27 (66) – 13 (33) 0.001 0.180 \0.001
25OHD: vitamin D
p difference between baseline and 12 months in all children
p* difference between baseline and 12 months in group A
p** difference between baseline and 12 months in group B
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In group A, at baseline, 14 (34 %) children were vitamin
D-insufficient and 7 (17 %) vitamin D-deficient, while in
group B 14 (36 %) were vitamin D-insufficient and 25
(64 %) vitamin D-deficient (Table 2).
A significant correlation was found between vitamin D
levels at baseline and AUCGH (q 0.444; p \ 0.001)
(Fig. 1), while no significant relationships were found
between vitamin D levels and IGF1 or auxological
parameters (data not shown).
After 12 months of GH treatment, height SD, weight,
WC and IGF1 significantly increased in all children, as
expected. An increase in serum vitamin D was found both
in all children (34.4 ± 16.4 vs. 24.4 ± 11.1 ng/ml;
p = 0.002) and in group A (38.5 ± 14 vs. 31.1 ± 11.1 ng/
ml; p \ 0.001) and group B (30 ± 17.7 vs. 17.3 ± 5.3 ng/
ml; p \ 0.001) (Fig. 2). A concomitant increase in AP was
found both in the whole population (266.1 ± 60.6 vs.
161.2 ± 70.6 IU/l; p = 0.016) and in the two groups of
children (244.8 ± 65.9 vs. 148.6 ± 33.5 IU/l; p = 0.042
in group A and 291.8 ± 47.6 vs. 175.8 ± 97 IU/l;
p = 0.035 in group B, respectively). No significant dif-
ference was found in Ca, P and PTH levels (Table 3).
When we grouped all children into those who showed an
increase in vitamin D (Nos. 67 with positive delta) and
those who failed to increase it (Nos. 13 with negative
delta), we found no significant difference in all clinical or
biochemical characteristics (data not shown). Overall, after
12 months of GH treatment, only 25 (31 %) children
remained vitamin D-insufficient and 15 (19 %) vitamin
D-deficient, with a significant increase in prevalence of
children with normal vitamind D levels (p = 0.001)
(Fig. 3). In group A, after 12 months, 9 children (22 %)
were vitamin D-insufficient and 5 (12 %) vitamin D-defi-
cient, without significant change in prevalence of each
category of vitamin D status from baseline. Conversely, in
group B we found a significant decrease in prevalence of
children with vitamin D-deficiency (26 vs. 64 %;
p = 0.001) and a significant increase in those with normal
vitamin D (33 vs. 0; p \ 0.001) (Table 2).
Discussion
Our data demonstrated a very high prevalence of hypovi-
taminosis D in Sicilian children affected by GHD, with an
improvement in vitamin D levels after 12 months of GH
treatment.
Hypovitaminosis D is a prevalent disorder in developing
countries and its prevalence varies widely between and
within regions, ranging between 30–90 %, according to the
cut-off value used within specific regions and indepen-
dently of latitude [16]. Our data showed a higher preva-
lence of hypovitaminosis D in children evaluated in the
winter seasons, in line with the data already known. Indeed,
a high prevalence of children and adolescents also showed
insufficient vitamin D levels in the winter in European
countries [17–19] and older age, female sex, higher lati-
tude, winter season, darker skin pigmentation, less sunlight
exposure and dietary habits are the main factors that are
significantly associated with lower vitamin D levels
[20, 21].
Vitamin D physiologically stimulates intestinal absorp-
tion of calcium and phosphate and renal reabsorption of
calcium and inhibits PTH from the parathyroid glands [22,
23]. A positive association between vitamin D and GH/
IGF1 axis is documented. Both GH and IGF1 increased the
production of vitamin D by cultured kidney cells and IGF1
stimulated vitamin D synthesis by the placenta [24]. IGF1
stimulates renal production of active vitamin D, which
Fig. 1 Correlation between vitamin D levels and area under the curve
(AUC) of GH (lg/l) at baseline in all patients
Fig. 2 Change in 25OHD levels from baseline to 12 months in all
children (left), in children enrolled between June and September
(group A) (mean) and in children enrolled between November and
February (group B) (right)
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increases calcium and phosphate availability in the body
and inhibits PTH secretion [25, 26]. These actions could be
responsible for bone status in active acromegaly, charac-
terized by significantly higher serum vitamin D and by an
increase in plasma calcium and phosphate and urinary
calcium excretion [7, 27]. In addition, a better vitamin D
status seems to contribute to the achievement of normal
IGF1 levels in children affected by GHD [10].
However, to date, there are no current definitive prev-
alence estimates available for vitamin D status in GHD
children and data about the effect of GH and IGF1 on
vitamin D in GHD children are controversial [8, 28–30].
In our cohort, a high percentage of children (75 %),
regardless of the season, showed low vitamin D levels
(\30 ng/ml) with normal serum levels of Ca, P and PTH,
despite a much higher prevalence in the winter seasons.
These data are partially in agreement with existing studies
on prevalence of hypovitaminosis D performed in children
grouped according to the seasons of evaluation [31],
although in our study the condition of GHD seems to
amplify this trend already documented in healthy children
of the above-mentioned study. Instead, if the overall prev-
alence of low vitamin D in our cohort of children at baseline
in the winter seasons is not higher than those detected in
healthy young subjects living in the South of Italy [32] (64
vs. 70 %), in summer seasons it is higher than expected (17
vs. 4.4 %), although after GH treatment the difference
becomes smaller (12 vs. 4,4 %). Indeed, 12 months of GH
treatment has proven effective in increasing vitamin D
levels, suggesting the main role of GH in influencing it. In
our opinion, probably a longer GH treatment could lead to
more similar prevalences. However, the possibility that the
negative influence of GHD on vitamin D levels is concealed
in the absence of light exposure and is more pronounced in
the summer seasons, for example due to the relatively high
melanin content of the skin, can not be excluded. In
addition, notably, in the above-mentioned study the subjects
enrolled were young adults with a mean age of 38 years,
while we enrolled children with a mean age of 10 years,
which are then more comparable to the healthy school-
children of the other study [31].
We found no effect of GH treatment on serum Ca, P and
PTH levels and these data are partially in line with the
literature. A few years ago Wright et al. [33] showed that
GH increases serum vitamin D levels independently of
circulating PTH in healthy subjects, assuming this as a
potential mechanism by which GH stimulates increases in
bone mass. Conversely, Ahmad et al. [34] demonstrated a
regulatory effect of GH on bone mineral metabolism by an
increase in serum calcium, phosphate and vitamin D and a
decrease in PTH in adult GHD patients. In these subjects a
PTH resistance status with increased serum PTH levels has
been documented and GH replacement seems to restore
PTH secretion rhythm in addition to increasing vitamin D
concentration [35]. Conversely, in line with our data, Bi-
anda et al. [5, 36] demonstrated the effect of GH on vitamin
D without changes in other bone parameters in both healthy
and GHD adult subjects. In addition, in support of our data,
the effect of GH replacement on bone turnover seems to be
independent of PTH, as some studies have failed to observe
any consistent change in PTH levels [28, 37]. Conversely,
the change in AP levels, documented in healthy children
during growth as a result of osteoblast activity [38], has
also been confirmed in our study. A limitation of this study
is represented by the lack of data regarding more specific
bone apposition and resorption markers and bone mineral
density, whose data were not available for all patients.
The absence of correlation between vitamin D and IGF1
levels both in baseline and after 12 months of GH treat-
ment further suggests a direct stimulatory effect of GH on
vitamin D, not necessarily mediated by IGF1 increase. This
finding is supported by the evidence that children with
lower GH values (expressed by the AUC of GH during
stimulation tests), and not IGF1, at baseline showed con-
comitant lower vitamin D levels. However, regardless of
the season of evaluation, in the entire cohort we found that
children with lower concentrations of vitamin D did not
have lower growth velocity after 12 months of treatment or
lower IGF1 concentrations both before and after 12 months
of GH treatment, probably because in all children GH dose
was modulated to steadily maintain IGF1 levels in the
normal range and a comparable growth velocity.
The relatively high prevalence of low vitamin D levels
remaining after 12 months of GH treatment, regardless of
the season, lead to the idea that GHD children could also
profit from vitamin D supplementation. Future prospective
interventional studies that include a control group, the
absence of which is a limitation of our study, may better
clarify this point.
Fig. 3 Percentage of vitamin D sufficiency ([30 ng/ml), insuffi-
ciency (20–30 ng/ml) and deficiency (\20 ng/ml) in GHD children at
baseline and after 12 months of GH treatment
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In conclusions, even in a sunny country hypovitaminosis
D is common in GHD children, more so in the winter, and
12 months of GH treatment slightly improves this condi-
tion. Vitamin D assessment should therefore be considered
routinely in GHD children both at diagnosis and during the
course of follow-up. Additional prospective studies with
longer follow-up will demonstrate whether long-standing
GH treatment can further reduce the high prevalence of low
vitamin D levels in GHD children.
Acknowledgments This research did not receive any specific grant
from any funding agency in the public, commercial or not-for-profit
sector.
Conflict of interest All authors declare that there is no conflict of
interest that could be perceived as prejudicing the impartiality of the
research reported.
References
1. Johansen JS, Pedersen SA, Jørgensen JO, Riis BJ, Christiansen C,
Christiansen JS, Skakkebaek NE (1990) Effects of growth hor-
mone (GH) on plasma bone Gla protein in GH-deficient adults.
J Clin Endocrinol Metab 70(4):916–919
2. Binnerts A, Swart GR, Wilson JH, Hoogerbrugge N, Pols HA,
Birkenhager JC, Lamberts SW (1992) The effect of growth
hormone administration in growth hormone deficient adults on
bone, protein, carbohydrate and lipid homeostasis, as well as on
body composition. Clin Endocrinol (Oxf) 37(1):79–87
3. Schlemmer A, Johansen JS, Pedersen SA, Jørgensen JO, Has-
sager C, Christiansen C (1991) The effect of growth hormone
(GH) therapy on urinary pyridinoline cross-links in GH-deficient
adults. Clin Endocrinol (Oxf) 35(6):471–476
4. Henry HL (2011) Regulation of vitamin D metabolism. Best
Pract Res Clin Endocrinol Metab 25(4):531–541
5. Bianda T, Hussain MA, Glatz Y, Bouillon R, Froesch ER, Sch-
mid C (1997) Effects of short-term insulin-like growth factor-I or
growth hormone treatment on bone turnover, renal phosphate
reabsorption and 1,25 dihydroxyvitamin D3 production in healthy
man. J Intern Med 241(2):143–150
6. Marcus R, Butterfield G, Holloway L, Gilliland L, Baylink DJ,
Hintz RL, Sherman BM (1990) Effects of short term adminis-
tration of recombinant human growth hormone to elderly people.
J Clin Endocrinol Metab 70(2):519–527
7. Kamenicky´ P, Blanchard A, Gauci C, Salenave S, Letierce A,
Lombe`s M, Brailly-Tabard S, Azizi M, Prie´ D, Souberbielle JC,
Chanson P (2012) Pathophysiology of renal calcium handling in
acromegaly: what lies behind hypercalciuria? J Clin Endocrinol
Metab 97(6):2124–2133
8. Amato G, Izzo G, La Montagna G, Bellastella A (1996) Low dose
recombinant human growth hormone normalizes bone metabo-
lism and cortical bone density and improves trabecular bone
density in growth hormone deficient adults without causing
adverse effects. Clin Endocrinol (Oxf) 45(1):27–32
9. Wei S, Tanaka H, Seino Y (1998) Local action of exogenous
growth hormone and insulin-like growth factor-I on di-
hydroxyvitamin D production in LLC-PK1 cells. Eur J Endocri-
nol 139(4):454–460
10. Ameri P, Giusti A, Boschetti M, Bovio M, Teti C, Leoncini G,
Ferone D, Murialdo G, Minuto F (2013) Vitamin D increases
circulating IGF1 in adults: potential implication for the treatment
of GH deficiency. Eur J Endocrinol 169(6):767–772
11. Soliman AT, Al Khalaf F, Alhemaidi N, Al Ali M, Al Zyoud M,
Yakoot K (2008) Linear growth in relation to the circulating
concentrations of insulin-like growth factor I, parathyroid hor-
mone, and 25-hydroxy vitamin D in children with nutritional
rickets before and after treatment: endocrine adaptation to vita-
min D deficiency. Metab Clin Exp 57:95–102
12. Marshall WA, Tanner JM (1969) Variations in pattern of pubertal
changes in girls. Arch Dis Child 44(235):230–291
13. Growth Hormone Research Society (2000) Consensus guidelines
for the diagnosis and treatment of growth hormone (GH) defi-
ciency in childhood and adolescence: summary statement of the
GH Research Society. J Clin Endocrinol Metab 85:3990–3993
14. Norman AW, Bouillon R, Whiting SJ, Vieth R, Lips P (2007)
13th workshop consensus for vitamin D nutritional guidelines.
J Steroid Biochem Mol Biol 103:204–205
15. McKenna MJ, Freaney R (1998) Secondary hyperparathyroidism
in the elderly: means to defining hypovitaminosis D. Osteoporos
Int 8(Suppl 2):S3–S6
16. Arabi A, El Rassi R, El-Hajj Fuleihan G (2010) Hypovitaminosis
D in developing countries-prevalence, risk factors and outcomes.
Nat Rev Endocrinol 6(10):550–561
17. Guillemant J, Taupin P, Le HT, Taright N, Allemandou A, Pe´re`s
G, Guillemant S (1999) Vitamin D status during puberty in
French healthy male adolescents. Osteoporos Int 10(3):222–225
18. Lehtonen-Veromaa M, Mo¨tto¨nen T, Irjala K, Ka¨rkka¨inen M,
Lamberg-Allardt C, Hakola P, Viikari J (1999) Vitamin D intake
is low and hypovitaminosis D common in healthy 9- to 15-year-
old Finnish girls. Eur J Clin Nutr 53(9):746–751
19. Guillemant J, Allemandou A, Cabrol S, Pe´re`s G, Guillemant S
(1998) Vitamin D status in the adolescent: seasonal variations and
effects of winter supplementation with vitamin D3. Arch Pediatr
5(11):1211–1215
20. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes
B, Eisman JA, El-Hajj Fuleihan G, Josse RG, Lips P, Morales-
Torres J, IOF Committee of Scientific Advisors (CSA), Nutrition
Working Group (2009) Global vitamin D status and determinants
of hypovitaminosis D. Osteoporos Int 20(11):1807–1820
21. Prentice A (2008) Vitamin D deficiency: a global perspective.
Nutr Rev 66(10 Suppl 2):S153–S164
22. Bouillon R, Carmeliet G, Daci E, Segaert S, Verstuyf A (1998)
Vitamin D metabolism and action. Osteoporos Int 8(Suppl
2):S13–S19
23. Norman AW (2008) From vitamin D to hormone D: fundamen-
tals of the vitamin D endocrine system essential for good health.
Am J Clin Nutr 88(2):491S–499S
24. Halhali A, Dı´az L, Sa´nchez I, Garabe´dian M, Bourges H, Larrea
F (1999) Effects of IGF-I on 1,25-dihydroxyvitamin D(3) syn-
thesis by human placenta in culture. Mol Hum Reprod
5(8):771–776
25. Ameri P, Giusti A, Boschetti M, Murialdo G, Minuto F, Ferone D
(2013) Interactions between vitamin D and IGF-I: from physi-
ology to clinical practice. Clin Endocrinol (Oxf) 79(4):457–463
26. Giustina A, Mazziotti G, Canalis E (2008) Growth hormone,
insulin-like growth factors, and the skeleton. Endocr Rev
29(5):535–559
27. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ
(2003) Pegvisomant-induced serum insulin-like growth factor-I
normalization in patients with acromegaly returns elevated
markers of bone turnover to normal. J Clin Endocrinol Metab
88(12):5650–5655
28. Wei S, Tanaka H, Kubo T, Ono T, Kanzaki S, Seino Y (1997)
Growth hormone increases serum 1,25-dihydroxyvitamin D lev-
els and decreases 24,25-dihydroxyvitamin D levels in children
with growth hormone deficiency. Eur J Endocrinol 136(1):45–51
29. Saggese G, Baroncelli GI, Bertelloni S, Cinquanta L, Di Nero G
(1993) Effects of long-term treatment with growth hormone on
J Endocrinol Invest
123
Author's personal copy
bone and mineral metabolism in children with growth hormone
deficiency. J Pediatr 122(1):37–45
30. Hansen TB, Brixen K, Vahl N, Jørgensen JO, Christiansen JS,
Mosekilde L, Hagen C (1996) Effects of 12 months of growth
hormone (GH) treatment on calciotropic hormones, calcium
homeostasis, and bone metabolism in adults with acquired GH
deficiency: a double blind, randomized, placebo-controlled study.
J Clin Endocrinol Metab 81(9):3352–3359
31. El-Hajj Fuleihan G, Nabulsi M, Choucair M, Salamoun M, Hajj
Shahine C, Kizirian A, Tannous R (2001) Hypovitaminosis D in
healthy schoolchildren. Pediatrics 107(4):E53
32. Carnevale V, Modoni S, Pileri M, Di Giorgio A, Chiodini I,
Minisola S, Vieth R, Scillitani A (2001) Longitudinal evaluation
of vitamin D status in healthy subjects from southern Italy:
seasonal and gender differences. Osteoporos Int 12(12):
1026–1030
33. Wright NM, Papadea N, Wentz B, Hollis B, Willi S, Bell NH
(1997) Increased serum 1,25-dihydroxyvitamin D after growth
hormone administration is not parathyroid hormone-mediated.
Calcif Tissue Int 61(2):101–103
34. Ahmad AM, Thomas J, Clewes A, Hopkins MT, Guzder R, I-
brahim H, Durham BH, Vora JP, Fraser WD (2003) Effects of
growth hormone replacement on parathyroid hormone sensitivity
and bone mineral metabolism. J Clin Endocrinol Metab
88(6):2860–2868
35. Lombardi G, Di Somma C, Vuolo L, Guerra E, Scarano E, Colao
A (2010) Role of IGF-I on PTH effects on bone. J Endocrinol
Invest 33(7 Suppl):22–26
36. Bianda T, Glatz Y, Bouillon R, Froesch ER, Schmid C (1998)
Effects of short-term insulin-like growth factor-I (IGF-I) or
growth hormone (GH) treatment on bone metabolism and on
production of 1,25-dihydroxycholecalciferol in GH-deficient
adults. J Clin Endocrinol Metab 83(1):81–87
37. Beshyah SA, Thomas E, Kyd P, Sharp P, Fairney A, Johnston DG
(1994) The effect of growth hormone replacement therapy in
hypopituitary adults on calcium and bone metabolism. Clin
Endocrinol (Oxf) 40(3):383–391
38. Savic´ L, Savic´ D (2008) Serum calcium and phosphorus con-
centration and alkaline phosphatase activity in healthy children
during growth and development. Med Pregl 61(7–8):393–399
J Endocrinol Invest
123
Author's personal copy
